Annaida Technologies

Executive Summary

Annaida Technologies is a Swiss biotech company pioneering an AI-driven metabolomic platform based on miniaturized Magnetic Resonance Spectroscopy (MRS). Their microchip technology enables non-invasive, real-time metabolic analysis of nanolitre-scale samples such as embryos, organoids, and single cells. The primary application is in fertility clinics, where the platform offers a non-invasive method for embryo selection, potentially improving IVF success rates. Additionally, it serves as a versatile tool for researchers in precision metabolomics. The company was founded in 2016 and is headquartered in Zug, Switzerland. Annaida's approach addresses key limitations in current metabolic analysis by miniaturizing MRS, making it accessible for small sample volumes without requiring labels or complex preparation. The integration of AI enhances data interpretation, offering actionable insights for clinical decision-making. While the company is private, its technology has the potential to disrupt both the fertility and broader life sciences research markets. However, it faces competition from other metabolomics and embryo assessment technologies. The company's stage and funding details are not publicly disclosed, indicating an early to mid-stage development phase.

Upcoming Catalysts (preview)

• Q4 2026Partnership with Major Fertility Clinic Network65% success
• Q2 2027Series B Funding Round Closing70% success
• Q1 2027Publication of Clinical Validation Study Results60% success